Mindfulness-based Stress Reduction for Multiple Sclerosis



Status:Completed
Conditions:Neurology, Neurology, Multiple Sclerosis
Therapuetic Areas:Neurology, Other
Healthy:No
Age Range:18 - Any
Updated:4/17/2018
Start Date:May 2015
End Date:May 30, 2017

Use our guide to learn which trials are right for you!

The primary purpose of this study is to assess the feasibility of mindfulness-based stress
reduction (MBSR) for adults with any type of multiple sclerosis. The secondary objectives are
to: 1) Explore the ability of MBSR to improve perceived stress and quality of life compared
to an education control group; and 2) Explore the durability of the effects of MBSR over one
year.


Inclusion Criteria:

- Men and women 18 years of age or older

- Definite relapsing remitting, secondary progressive, or primary progressive MS by
revised McDonald criteria;

- Expanded Disability Severity Scale ≤ 8 at baseline;

- Stable on MS disease modifying, anxiolytic, or antidepressant medications for three
months prior to baseline visit;

- Mild to moderate stress defined by a score of ≥ 10 on the Perceived Stress Scale at
screening;

- Ability to read and write in English;

- Willingness to provide informed consent and comply with study activities, including
weekly MBSR sessions and daily practice or weekly Education Control classes.

Exclusion Criteria:

- MBSR or cognitive behavioral therapy training within the last 5 years;

- Current regular meditation or yoga practice (weekly or more often);

- MS exacerbation within 30 days of Baseline Visit;

- Mini-Mental Status Examination (MMSE) score of ≤ 26 at Screening Visit;

- Active suicidal ideation (Beck Depression Inventory) at Screening Visit;

- Reported or medically recorded diagnoses of current serious psychological disorders
other than depression and anxiety;

- Other current life-threatening or severely disabling physical disorders;

- Positive pregnancy urine test at Baseline and women planning pregnancy during the
study period (contraception not required);

- Cancer, other than basal or squamous skin cancers; or

- Inability or unwillingness of individual or legal guardian/representative to give
written informed consent.
We found this trial at
1
site
Portland, Oregon 97201
Principal Investigator: Angela Senders, ND, MCR
Phone: 503-552-1743
?
mi
from
Portland, OR
Click here to add this to my saved trials